Buerger's Disease: Symptoms, causes and treatment

Have you ever heard of a disease that is almost entirely caused by smoking — yet remains widely unknown? A condition where the very blood vessels keeping your hands and feet alive slowly get choked off, sometimes leading to amputation? That disease is real, and it has a name: Buerger’s Disease.

Let’s break it all down — plainly, honestly, and in a way that actually makes sense.

What is Buerger’s Disease?

In the simplest terms possible, Buerger’s Disease — medically known as Thromboangiitis Obliterans (TAO) — is a condition where small and medium-sized blood vessels in the arms and legs become inflamed and blocked. Think of it like a garden hose that gets clogged and squeezed from the outside. Blood can’t flow properly, tissue starts to starve, and eventually, in the worst cases, fingers and toes begin to die.

It sounds extreme. But it happens. And more often than people realize.

Epidemiologically, Buerger’s Disease is more common in parts of Asia, the Middle East, and Eastern Europe, where heavy tobacco use is widespread. In the United States, it affects roughly 8–12 per 100,000 people. Globally, it predominantly strikes young men between the ages of 20 and 45, though women are increasingly being diagnosed — likely due to rising smoking rates among females. It is rare in non-smokers. Almost unheard of, in fact.

How Does It Occur?

Here’s where it gets interesting. Unlike many vascular diseases that stem from fatty plaque buildup (atherosclerosis), Buerger’s Disease works differently. It’s an inflammatory process.

When someone — particularly a heavy tobacco user — is exposed to certain substances in tobacco, the immune system seems to turn against the blood vessel walls. The body launches an inflammatory attack on the inner lining (intima) of small and medium vessels. Blood clots begin to form inside these inflamed vessels. Over time, the clots and inflammation grow together, literally obliterating (blocking off) the lumen of the vessel.

What makes this unique is that the structure of the vessel wall itself remains relatively intact — it’s the inside that gets progressively destroyed. This explains the term “thromboangiitis” — thrombosis (clotting) plus angiitis (vessel inflammation).

As the blockage worsens, tissues beyond the blockage receive less and less blood. Less blood means less oxygen. Less oxygen means tissue death — starting at the fingertips and toes, and potentially spreading further.

What Are the Causes of Buerger’s Disease?

The cause of Buerger’s Disease is not a mystery — it is almost always tied to tobacco. However, it isn’t as simple as “smoking causes it.” The exact mechanism involves a complex interplay of immune responses, genetic susceptibility, and direct toxic effects of tobacco compounds on vessel walls. Understanding what drives this disease is critical, because it directly shapes treatment decisions.

Tobacco use (primary cause — up to 95–100% of cases): This is the big one. Virtually every patient diagnosed with Buerger’s Disease is a current or former tobacco user. This includes cigarettes, cigars, chewing tobacco, and even smokeless tobacco products. Studies suggest that tobacco is implicated in nearly 95–100% of TAO cases. The toxic compounds in tobacco trigger an immune-mediated inflammatory reaction in vessel walls, leading to clot formation and progressive blockage.

Genetic predisposition: Not every smoker develops this disease, which strongly suggests that genetics play a role. Certain HLA (Human Leukocyte Antigen) subtypes — specifically HLA-A9, HLA-B5, and HLA-DR4 — appear to increase susceptibility. This could explain why some heavy smokers never develop TAO while others develop it with moderate use.

Autoimmune mechanisms: Research points toward an autoimmune component. The body may produce antibodies against its own endothelial (vessel lining) cells, triggered by tobacco antigens. This immune reaction perpetuates the inflammation long after initial exposure.

Infections (possible contributory factor): Some studies have proposed a link between oral bacteria, particularly Treponema species, and the disease. The theory is that dental infections or periodontal disease may contribute to vessel inflammation in genetically susceptible individuals — though this remains under investigation.

Risk Factors

Not everyone who smokes will develop Buerger’s Disease, and not everyone with the disease is an identical risk profile. Understanding who is most vulnerable helps with early detection. Risk factors operate on a spectrum — some are lifestyle-related and entirely preventable, while others are beyond a person’s control. Identifying these factors early could mean the difference between keeping a limb and losing one.

Heavy tobacco use — The single most significant risk factor. The more you smoke and the longer you do it, the higher your risk. This is the risk factor that matters most.

Young age (20–45 years) — Unlike most vascular diseases that strike the elderly, TAO predominantly affects young adults.

Male sex — Historically more common in men, though this gap is narrowing.

South Asian, Middle Eastern, or Eastern European ethnicity — Geographic and ethnic background elevates baseline risk.

Genetic predisposition — Family history of autoimmune or vascular conditions.

Poor oral hygiene / periodontal disease — Emerging evidence links dental infections to disease flares.

Cold climate exposure — Cold-induced vasospasm may worsen or trigger symptoms.

Symptoms of Buerger’s Disease

The symptoms of Buerger’s Disease don’t show up all at once. They creep in — quietly at first, then more aggressively as vessels become more blocked. Here’s what to watch for and why each symptom happens:

Intermittent claudication (pain while walking): The most common early symptom. As blood flow to leg muscles reduces, they don’t get enough oxygen during activity — causing cramping pain. Rest relieves it temporarily.

Rest pain: As the disease progresses, pain occurs even at rest — typically in the fingers and toes. This is a red flag for critical limb ischemia. The tissue is now being starved of blood even when the body is still.

Colour changes in the hands and feet: Fingers or toes may appear pale (white), then bluish (cyanotic), then red — a classic triad called Raynaud’s phenomenon. This happens because vessel spasm and blockage disrupt normal blood flow patterns.

Cold sensitivity: Affected limbs feel abnormally cold to touch. Reduced blood flow means reduced heat delivery.

Superficial thrombophlebitis: Painful, inflamed cords just under the skin — caused by clotting in small superficial veins. This occurs in roughly 40% of TAO patients and can be an early diagnostic clue.

Non-healing ulcers and gangrene: In severe or untreated cases, wounds at the tips of digits refuse to heal. Without blood, tissue cannot repair itself — leading to gangrene and potential amputation.

Differential Diagnosis

Because Buerger’s Disease shares many symptoms with other vascular and autoimmune conditions, getting the diagnosis right is not always straightforward. Misdiagnosis can delay treatment and cause serious harm. Several conditions mimic TAO closely, and clinicians must systematically rule them out before confirming the diagnosis. This process of elimination is what makes a thorough workup so important.

Atherosclerosis obliterans: The most common look-alike. Both cause limb ischemia. However, atherosclerosis typically affects older patients with risk factors like hypertension, diabetes, and hyperlipidemia — while TAO strikes younger smokers with no atherosclerotic risk factors. Angiography findings differ significantly.

Raynaud’s Disease / Phenomenon: Both conditions cause colour changes and cold sensitivity in extremities. However, Raynaud’s is typically benign and doesn’t cause tissue death or non-healing ulcers.

Systemic Lupus Erythematosus (SLE) with vasculitis: Can cause digital ischemia and ulcers. Distinguished by serological markers (ANA, anti-dsDNA) which are negative in TAO.

Antiphospholipid Syndrome: Causes recurrent clotting but usually involves larger vessels and has positive anticardiolipin antibodies.

Embolic disease: Clots travelling from the heart can block peripheral vessels. Echocardiography and cardiac workup help rule this out.

Scleroderma: Causes digital ischemia but is accompanied by skin thickening and a positive ANA.

How to Diagnose Buerger’s Disease?

So how do doctors actually confirm this disease? There’s no single blood test that says “yes, this is TAO.” Instead, diagnosis relies on a combination of clinical criteria and investigative findings — and one investigation stands above the rest.

The gold standard investigation is digital subtraction angiography (DSA) — or more broadly, angiography of the affected limb. Here’s why it matters and what it shows:

Angiography involves injecting a contrast dye into the blood vessels and taking X-ray images to visualize blood flow. In Buerger’s Disease, angiography reveals a very specific and recognizable pattern:

Segmental occlusions (blockages in patches) of small and medium distal vessels

“Corkscrew collaterals” — tiny new blood vessels that spiral around the blocked areas, trying to reroute blood flow. This is pathognomonic (virtually diagnostic) of TAO.

Normal-appearing proximal vessels (no atherosclerotic plaques)

Involvement of both upper and lower extremities

In addition to angiography, clinicians use the Shionoya or Olin criteria for diagnosis — which include: age under 45, current or recent tobacco use, distal limb ischemia, no proximal embolic source, and no atherosclerotic risk factors.

Other investigations include:

Full blood count, ESR, CRP (to rule out infection or systemic inflammation)

Autoimmune panel (ANA, ANCA, anticardiolipin — to rule out other vasculitides)

Echocardiography (to exclude embolic source)

Doppler ultrasound (to assess blood flow non-invasively)

Biopsy — rarely done, but histopathology confirming inflammatory thrombus with preserved vessel wall architecture is definitive proof

Treatment of Buerger’s Disease

Here’s the honest truth about treating Buerger’s Disease: there is no cure. But there is one treatment so effective that it can stop the disease in its tracks — and it costs nothing. The entire approach to management revolves around controlling symptoms, improving blood flow, and above all, preventing progression.

Gold Standard Treatment: Complete and Permanent Smoking Cessation

Stopping tobacco use entirely is the single most important and evidence-based treatment for TAO. This is not an exaggeration. Studies consistently show that patients who completely quit smoking experience stabilization of disease, healing of ulcers, and dramatically reduced rates of amputation. Even a small amount of residual tobacco use — even occasional smoking or smokeless tobacco — can keep the disease active and progressing.

Smoking cessation support includes:

Nicotine replacement therapy (patches, gum) — with caution, as nicotine itself may sustain the disease

Pharmacotherapy: varenicline (Champix/Chantix) or bupropion

Behavioral counseling and support programs

Medical Management

Prostaglandins (Iloprost): Intravenous iloprost, a prostaglandin analogue, is the most commonly used drug for TAO. It helps dilate blood vessels, reduces clotting, and promotes ulcer healing. It is particularly useful when surgical options are not feasible.

Antiplatelet therapy: Aspirin is routinely used to reduce clot formation.

Anticoagulants: Used selectively in acute thrombotic episodes.

Calcium channel blockers: Help manage vasospasm, especially in cold-sensitive patients.

Pain management: NSAIDs, opioids (in severe rest pain), or spinal cord stimulation for refractory pain.

Surgical and Interventional Options

When medical treatment isn’t enough, especially in critical limb ischemia, intervention may be needed.

Endovascular therapy (angioplasty/stenting): A 2026 retrospective study by Rodoplu reported a technical success rate of 92% with endovascular therapy in TAO-related critical limb ischemia, with better outcomes in younger patients and those who stopped smoking.

Surgical bypass grafting: Used when suitable vessels are available. However, the distal and diffuse nature of TAO often limits bypass options.

Sympathectomy: Cutting the sympathetic nerves to reduce vasospasm and improve blood flow to the extremities.

Amputation: A last resort when gangrene is irreversible and limb salvage is no longer possible.

Emerging and Adjunctive Therapies

Stem cell therapy: Autologous bone marrow or peripheral blood stem cell infusions are being investigated as a way to promote new vessel growth (therapeutic angiogenesis) in patients with no surgical options. Results are promising but still experimental.

Traditional herbal medicine: Research into plant-based treatments is ongoing. A 2026 study explored the pharmacological properties of Asplenium ruprechtii — a traditional Chinese herb historically used for thromboangiitis obliterans — identifying promising bioactive compounds, though clinical application remains in early stages.

References

Kim JY, Lee YT, Seo JW. Histopathologically Confirmed Coronary Thromboangiitis Obliterans Successfully Treated With Surgical Revascularization. Ann Thorac Surg Short Rep. 2025;4(1):65–68. doi: 10.1016/j.atssr.2025.08.019. PMID: 42027477.
Rodoplu O. Long-term outcomes of endovascular therapy in Buerger disease with critical limb ischemia: a retrospective observational study. Int Angiol. 2026 Apr 22. doi: 10.23736/S0392-9590.26.05528-8. PMID: 42017702.
Ma XL, Tian JJ, Wang F, Jiang ZB. Chemical Profiling and Virtual Pharmacological Analysis of Asplenium ruprechtii Sa. Kurata. Rapid Commun Mass Spectrom. 2026;40(14):e70078. doi: 10.1002/rcm.70078. PMID: 42011822.
Olin JW. Thromboangiitis Obliterans (Buerger’s Disease). N Engl J Med. 2000;343(12):864–869. doi: 10.1056/NEJM200009213431207.
Dargon PT, Landry GJ. Buerger’s Disease. Ann Vasc Surg. 2012;26(6):871–880. doi: 10.1016/j.avsg.2011.11.005.
Piazza G, Creager MA. Thromboangiitis Obliterans. Circulation. 2010;121(14):1858–1861. doi: 10.1161/CIRCULATIONAHA.110.942383.
Fazeli B, Ravari H. Definition, Classification, and Pathogenesis of Buerger’s Disease. In: Buerger’s Disease — Diagnostic and Therapeutic Approaches. Springer; 2016. doi: 10.1007/978-3-319-23906-7_1.
Cacione DG, Macedo CR, Baptista-Silva JCC. Pharmacological treatment for Buerger’s disease. Cochrane Database Syst Rev. 2020;(5):CD011033. doi: 10.1002/14651858.CD011033.pub4.